INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.810
-0.010 (-0.55%)
Dec 19, 2025, 3:06 PM EST - Market open
INmune Bio Employees
As of December 31, 2024, INmune Bio had 22 total employees, including 13 full-time and 9 part-time employees. The number of employees increased by 5 or 29.41% compared to the previous year.
Employees
22
Change (1Y)
5
Growth (1Y)
29.41%
Revenue / Employee
$2,273
Profits / Employee
-$2,267,591
Market Cap
48.12M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | 5 | 29.41% |
| Dec 31, 2023 | 17 | 7 | 70.00% |
| Dec 31, 2022 | 10 | 0 | - |
| Dec 31, 2021 | 10 | 5 | 100.00% |
| Dec 31, 2020 | 5 | 1 | 25.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INMB News
- 14 days ago - Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform - GlobeNewsWire
- 18 days ago - INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients - GlobeNewsWire
- 4 weeks ago - INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference - GlobeNewsWire
- 7 weeks ago - INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update - GlobeNewsWire
- 2 months ago - INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 - GlobeNewsWire
- 4 months ago - INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment - GlobeNewsWire